Synergy Pharmaceuticals, a drug developer focused on gastrointestinal disorders and diseases, has concluded its merger with Callisto Pharmaceuticals, a biotechnology company that develops novel therapeutics to treat cancer.
 
Under the terms of the merger agreement, each outstanding share of Callisto common stock was converted into one share of Synergy common stock and the approximately 22.3 million shares of Synergy held by Callisto were canceled. Callisto’s common stock will no longer be traded on the OTC QB.